Skip to main content
. 2018 May 18;2018:247–256.

Figure 1.

Figure 1.

Schematic summary of the proposed methodology. Pharmacogenomic information (PharmGKB) was combined with population genetic data (23andMe) to find associations between drugs. Reports of ADEs or outcomes (AEOLUS) were combined with 23andMe data to find associated outcomes with potential genetic associations.